Literature DB >> 3731974

Cisapride offsets dopamine-induced slowing of fasting gastric emptying.

S A Müller-Lissner, C Fraas, A Härtl.   

Abstract

The effect of cisapride, a new gastrokinetic drug, on gastroduodenal motility was tested in six healthy volunteers. In order to obtain a model for slowed gastric emptying, dopamine was infused at a rate of 8 micrograms/kg/min. Dopamine significantly slowed the fractional emptying rate of fasting gastric contents from 5.14 +/- 0.37 to 1.45 +/- 0.67 %/min. Injection of either 10 mg of cisapride or 10 mg of metoclopramide restored emptying rate to normal (5.87 +/- 0.56 and 5.62 +/- 0.61 %/min, respectively). When cisapride was given without dopamine background, emptying was only moderately enhanced. Reflux of bile salts was not significantly affected by either cisapride or dopamine alone. When given on a dopamine background, however, both metoclopramide and cisapride decreased bile salt reflux below control values without any active treatment. It is concluded that emptying of fasting gastric contents can be speeded by cisapride, particularly when emptying is slowed by dopamine. A clear effect on bile salt reflux cannot be demonstrated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3731974     DOI: 10.1007/bf01296047

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  18 in total

Review 1.  Metoclopramide.

Authors:  K Schulze-Delrieu
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

2.  Gastrointestinal actions of metoclopramide. An experimental study.

Authors:  H I Jacoby; D A Brodie
Journal:  Gastroenterology       Date:  1967-04       Impact factor: 22.682

3.  Increased reflux of bile into the stomach in patients with gastric ulcer.

Authors:  J Rhodes; D E Barnardo; S F Phillips; R A Rovelstad; A F Hofmann
Journal:  Gastroenterology       Date:  1969-09       Impact factor: 22.682

4.  Effect of dopamine on pentagastrin-stimulated gastric acid secretion and mucosal blood flow in dogs with gastric fistula.

Authors:  C P Hovendal; K Bech; F Gottrup; D Andersen
Journal:  Scand J Gastroenterol       Date:  1982-01       Impact factor: 2.423

5.  Effect of dopamine on pentagastrin-stimulated gastric antral motility in dogs with gastric fistula.

Authors:  K Bech; C P Hovendal; D Andersen
Journal:  Scand J Gastroenterol       Date:  1982-01       Impact factor: 2.423

6.  Effect of metoclopramide on gastric function in man.

Authors:  A M Connell; J D George
Journal:  Gut       Date:  1969-08       Impact factor: 23.059

7.  Novel approach to quantify duodenogastric reflux in healthy volunteers and in patients with type I gastric ulcer.

Authors:  S A Müller-Lissner; C J Fimmel; A Sonnenberg; N Will; W Müller-Duysing; F Heinzel; R Müller; A L Blum
Journal:  Gut       Date:  1983-06       Impact factor: 23.059

8.  Effects of metoclopramide and bethanechol on delayed gastric emptying present in gastroesophageal reflux patients.

Authors:  R W McCallum; S M Fink; E Lerner; D M Berkowitz
Journal:  Gastroenterology       Date:  1983-06       Impact factor: 22.682

9.  Effect of dopamine on bethanechol-stimulated gastric antral motility in dogs with gastric fistula.

Authors:  K Bech; C P Hovendal
Journal:  Scand J Gastroenterol       Date:  1982-10       Impact factor: 2.423

10.  Measurement of gastric emptying in dyspeptic patients: effect of a new gastrokinetic agent (cisapride).

Authors:  R Jian; F Ducrot; C Piedeloup; J Y Mary; Y Najean; J J Bernier
Journal:  Gut       Date:  1985-04       Impact factor: 23.059

View more
  13 in total

1.  A comparison of gastric emptying rate after cimetidine and ranitidine measured by applied potential tomography.

Authors:  M C Mushambi; T N Trotter; P Barker; D J Rowbotham
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

2.  Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa.

Authors:  D Deleu; G Ebinger; Y Michotte
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Slow gastric emptying induced by high fat content of meal accelerated by cisapride administered rectally.

Authors:  G Stacher; G V Granser; H Bergmann; A Kugi; G Stacher-Janotta; J Höbart
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

4.  The influence of levodopa on gastric emptying in man.

Authors:  D R Robertson; A G Renwick; N D Wood; N Cross; B S Macklin; J S Fleming; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

5.  Cisapride reduces postoperative gastrocaecal transit time after cardiac surgery in children.

Authors:  L Bindl; S Buderus; M Ramirez; P Kirchhoff; M J Lentze
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

Review 6.  Management of gastrointestinal motility disorders. A practical guide to drug selection and appropriate ancillary measures.

Authors:  J R Malagelada; E Distrutti
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 7.  Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders.

Authors:  R W McCallum; C Prakash; D M Campoli-Richards; K L Goa
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

Review 8.  Pharmacokinetic considerations in gastrointestinal motor disorders.

Authors:  G S Hebbard; W M Sun; F Bochner; M Horowitz
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

9.  Fat preload delays gastric emptying: reversal by cisapride.

Authors:  G Stacher; H Bergmann; G Gaupmann; C Schneider; A Kugi; J Höbart; A Binder; G Mittelbach-Steiner
Journal:  Br J Clin Pharmacol       Date:  1990-12       Impact factor: 4.335

Review 10.  A risk-benefit assessment of cisapride in the treatment of gastrointestinal disorders.

Authors:  J Tack; G Coremans; J Janssens
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.